Treats clinically important hypotension resulting primarily from vasodilation in the…. ANDA 211079, held by Amneal. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 211079 (Phenylephrine Hydrochloride), held by Amneal, was first approved by FDA on Jul 5, 2018, with 2 approved supplements and 0 published complete response letters.
Phenylephrine hydrochloride injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 5, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Sep 1, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 1, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 5, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters